We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Sanofi said an oral treatment for multiple sclerosis, tolebrutinib, met its key goal in a Phase 3 study, potentially clearing the way for regulatory approval, although in two other studies ...

Sanofi and Regeneron’s blockbuster drug Dupixent successfully treated patients with chronic spontaneous urticaria, an inflammatory skin disease, in a late-stage trial, the companies announced on ...

By Ludwig Burger (Reuters) -Sanofi's most advanced multiple sclerosis drug candidate has missed the main goal of two late-stage trials to treat relapsing forms of the disease, but in a positive ...

Following an FDA rejection last year, the partners plan to resubmit their application for approval of Dupixent in chronic spontaneous urticaria.

A pill Novo acquired produced modest weight loss but raised safety questions. Elsewhere, Sanofi detailed the silver lining it found in a recent study and a heart drug developer’s shares surged.

Sanofi won approval for the use of a drug combination with its Sarclisa infusion to treat certain types of newly diagnosed ...

Sanofi said this morning that its pipeline includes ... build-up to an R&D presentation to investors that will be held in New York later today, and also after the France-headquartered group ...

Since an initial FDA go-ahead in 2020, Sanofi’s Sarclisa has been specifically approved for patients with previously treated ...

A Sanofi experimental drug for multiple sclerosis delayed disability progression in a late-stage trial, but failed to reduce episodes of new or worsening symptoms compared to an existing treatment ...

Sanofi has made a late entry to the radioligand party, paying 100 million euros ($110 million) upfront for global rights to a neuroendocrine tumor treatment that is nearing a filing for approval.

Although the latest news from the laboratory was mixed for pharmaceutical company Sanofi (NASDAQ: SNY) on Tuesday, investors gave the company the benefit of the doubt. They bid the share price up ...